Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

GLUCO-SCAN

Financiado

Cerrado

Deuterium labeling of GLUCOse improves magnetic resonance imaging Sensitivity to...

Deuterium labeling of GLUCOse improves magnetic resonance imaging Sensitivity to CANcer metabolism The targeted scientific breakthrough of GLUCO-SCAN is the development and clinical evaluation of a disruptive whole-body molecular imaging concept for cancer assessment. The only currently established whole-body molecular imaging... ver más

30/11/2028

MEDIZINISCHE UNIVE...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

MEDIZINISCHE UNIVERSITAET WIEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-12-01

ERC-2022-COG: ERC CONSOLIDATOR GRANTS Scope:Objectives

I+D

Cerrada hace 2 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

MEDIZINISCHE UNIVERSITAET WI...

Lider

Proyectos interesantes

Hyperpolarized MRI

Medical Technol...

Applied Physics

2M€ Cerrado

LF13CMRI

Medical Technol...

Applied Physics

190K€ Cerrado

CHUS10-1E-1382

Medical Technol...

Applied Physics

825K€ Cerrado

RTI2018-095800-A-I00

Medical Technol...

Applied Physics

29K€ Cerrado

FPA2016-78987-P

Medical Technol...

Applied Physics

182K€ Cerrado

BES-2012-055741

Medical Technol...

Applied Physics

43K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 59 meses Fecha Inicio: 2023-12-01
Fecha Fin: 2028-11-30

Líder del proyecto

MEDIZINISCHE UNIVERSITAET WIEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The targeted scientific breakthrough of GLUCO-SCAN is the development and clinical evaluation of a disruptive whole-body molecular imaging concept for cancer assessment. The only currently established whole-body molecular imaging device is positron emission tomography (PET). Glucose (Glc)-sensitive PET is widely used in cancer diagnosis and treatment assessment, but has several major limitations: PET involves harmful ionizing radiation, is expensive, not widely available, and cannot differentiate between cancer-specific and normal cellular glucose uptake. These limitations prohibit an even more widespread use of PET, e.g. for screening. We propose a new Magnetic Resonance Imaging (MRI) concept, whole-body deuterium metabolic imaging (DMI) that will overcome these limitations.Deuteration is a simple chemical procedure with which it is possible to artificially label a broad range of molecules with an equally broad range of potential applications, e.g., targeting Glc metabolism in cancer. After ingestion, this labeled Glc is metabolized in cells and the label is transferred to all metabolic products, which can be tracked by DMI.Building on our recent preliminary results in Nature Biomed, we propose a combination of novel MRI hardware, dynamic spectroscopic data sampling, deep learning algorithms, and a clinical validation to answer the following three research questions in a 5-year project:(i) Is DMI a viable alternative for whole-body cancer assessment?(ii) How is DMI positioned compared to Glc-sensitive PET?(iii) Can DMI be performed on widely available MRI systems and simultaneous with standard MRI?GLUCO-SCAN will fill a gap in current medical imaging by offering an alternative for whole-body PET examinations and potentially even for screening of high risk populations. Ultimately, it will pave the way for a new generation of MR scanners with all-in-one whole-body imaging capability that would capture morphologic and molecular information simultaneously.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores